> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-160/
- Published: 2017-12-10T12:00:00.000Z
- Updated: 2026-09-14T23:06:52.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5140315

[**Workshop on Software Precertification Program**](https://www.fdaweb.com/workshop-on-software-precertification-program/)  
*Federal Register* notice: FDA announces a 1/30-31/2018 public workshop entitled “Fostering Digital Health Innovation: Developing the Software Precertification Program.” 12/08/2017

[**Comments Sought on Oncology Center of Excellence Functions**](https://www.fdaweb.com/comments-sought-on-oncology-center-of-excellence-functions/)  
*Federal Register* notice: FDA announces a 3/15/2018 public meeting entitled “Oncology Center of Excellence: Listening Session.” 12/08/2017

[**Comments Sought on User Fee Performance Assessment**](https://www.fdaweb.com/comments-sought-on-user-fee-performance-assessment/)  
*Federal Register* notice: FDA seeks comments on a statement of work to assess current practices when communicating during IND development and identify best practices and areas of improvement. 12/08/2017

[**FDA Posts Annual Report on Postmarketing Study Requirements**](https://www.fdaweb.com/fda-posts-annual-report-on-postmarketing-study-requirements/)  
*Federal Register* notice: FDA posts its annual report on the status of drug/biologic postmarketing requirements and postmarketing commitments. 12/08/2017

[**Guide on Pediatric Rare Disease Drug Development**](https://www.fdaweb.com/guide-on-pediatric-rare-disease-drug-development/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Pediatric Rare Diseases — A Collaborative Approach for Drug Development Using Gaucher Disease as a Model.” 12/07/2017

[**Guide on Serological Tests to Reduce T. Cruzi Infections**](https://www.fdaweb.com/guide-on-serological-tests-to-reduce-t-cruzi-infections/)  
*Federal Register* notice: FDA makes available a guidance entitled “Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Blood and Blood Components.” 12/06/2017

[**FDA Comment Period Extended on Reducing Regulation Burdens**](https://www.fdaweb.com/fda-comment-period-extended-on-reducing-regulation-burdens/)  
*Federal Register* notice: FDA extends the comment period on a 9/8 notice seeking input on existing regulations and related paperwork requirements that could be modified, repealed, or replaced to achieve meaningful burden reduction. 12/06/2017

[**FDA Performance Board Members Announced**](https://www.fdaweb.com/fda-performance-board-members-announced/)  
*Federal Register* notice: FDA announces the names of the members who will serve on its Performance Review Board. 12/05/2017

[**Required Notice on Biosimilar Patent Infringement Suit**](https://www.fdaweb.com/required-notice-on-biosimilar-patent-infringement-suit/)  
*Federal Register* notice: FDA provides notice that an applicant for a proposed biosimilar product notified the agency that a patent infringement action was filed in connection with the applicant’s BLA (AbbVie, Inc., et al. v. Boehringer Ingelheim Intl. GMBH et al). 12/05/2017